Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | GFER | P55789 | 1/20 | 0.49 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 2/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.45 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | TDP2 | O95551 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9198835 | 0.85 | NR1H3 (0.49) | LMNAGFERAPOBEC3GTDP1CNR1 | |
| SCHEMBL9354103 | 0.81 | ALDH1A1 (0.55) | CNR1NR1H3ALDH1A1NR1H2MEN1 | |
| SCHEMBL8235257 | 0.79 | AVPR2 (0.46) | LMNAGFERAPOBEC3GTDP1CNR1 | |
| SCHEMBL9259478 | 0.79 | NOTUM (0.50) | LMNACNR1NOTUMNR1H3ALDH1A1 | |
| Dimethylamine SCHEMBL7655386 | 0.79 | ADORA2B (0.43) | LMNANR1H3ALDH1A1NR1H2KDM4E | |
| SCHEMBL9184719 | 0.78 | LMNA (0.42) | LMNAGFERAPOBEC3GTDP1CNR1 | |
| SCHEMBL9181039 | 0.76 | LMNA (0.40) | LMNAGFERAPOBEC3GTDP1CNR1 | |
| SCHEMBL8233071 | 0.75 | TSHR (0.61) | LMNAALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL10486744 | 0.72 | APOBEC3G (0.55) | LMNAGFERAPOBEC3GTDP1CNR1 | |
| SCHEMBL8233155 | 0.72 | APOBEC3G (0.68) | LMNAGFERAPOBEC3GTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5436252-A | Antiischemic agents, stroke, Alzheimer's or Parkinson's diseases | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-07-25 | — | — | US | claimed |
| US-4946856-A | 5-phenyl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-08-07 | — | — | US | claimed |
| US-20100234402-A1 | METHODS AND COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2010-09-16 | — | — | US | disclosed |
| WO-2008150509-A1 | METHODS AND COMPOSITIONS FOR TREATING SPINAL MUSCULAR ATROPHY | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2008-12-11 | — | — | WO | disclosed |
| US-20060286167-A1 | Compositions and methods for the treatment of neurodegenerative diseases | STAUNTON JANE | 2006-12-21 | — | — | US | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119329-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| US-5436252-A | Antiischemic agents, stroke, Alzheimer's or Parkinson's diseases | MERRELL DOW PHARMACEUTICALS INC. (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0273310-B1 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants | MERRELL DOW PHARMA (US) | 1995-06-21 | — | — | EP | disclosed |
| EP-0273309-B1 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders | MERRELL DOW PHARMA (US) | 1995-01-11 | — | — | EP | disclosed |
| US-4946856-A | 5-phenyl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants | MERRELL DOW PHARMACEUTICALS INC. (US) | 1990-08-07 | — | — | US | disclosed |
| EP-0280867-A1 | Process for the preparation of 5-aryl-2,4-dialkyl-3H-1,2,4-triazole-3-thiones | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-09-07 | — | — | EP | disclosed |
| EP-0273310-A2 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use as anticonvulsants | MERRELL PHARMACEUTICALS INC. (US) | 1988-07-06 | — | — | EP | disclosed |
| EP-0273309-A2 | 5-Aryl-3H-1,2,4-triazol-3-ones and their use in the treatment of neurodegenerative disorders | MERRELL DOW PHARMACEUTICALS INC. (US) | 1988-07-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | LMNA 166/4885GFER 3274/4885APOBEC3G 411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.